Last update 08 May 2025
CytoPathfinder, Inc.

CytoPathfinder, Inc.

Private Company|2004|Tokyo-to, Japan|
www.cytopathfinder.com

Overview

Tags

Digestive System Disorders
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Top 5 Drug TypeCount
Small molecule drug1

Related

2
Drugs associated with CytoPathfinder, Inc.
PG-103(CytoPathfinder, Inc.)
Target-
Mechanism-
Active Org.
CytoPathfinder, Inc.CytoPathfinder, Inc.
Originator Org.
CytoPathfinder, Inc.CytoPathfinder, Inc.
Active Indication
Pancreatitis
Inactive Indication-
Drug Highest PhaseClinical
First Approval Ctry. / Loc.-
First Approval Date-
PG-092
Target
CCR2
Mechanism
CCR2 antagonists
Active Org.-
Originator Org.
CytoPathfinder, Inc.CytoPathfinder, Inc.
Active Indication-
Inactive Indication
Inflammation
Drug Highest PhasePending
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with CytoPathfinder, Inc.
Login to view more data
0 Patents (Medical) associated with CytoPathfinder, Inc.
Login to view more data
3
Literatures (Medical) associated with CytoPathfinder, Inc.
Electrochemistry (Tokyo, Japan)
Cell array and application to cell function interpretation
Bunshi Kokyukibyo
Proteomics in drug development
Seibutsu Kogaku Kaishi
Approach to cell systems
100 Deals associated with CytoPathfinder, Inc.
Login to view more data
100 Translational Medicine associated with CytoPathfinder, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
PG-103(CytoPathfinder, Inc.)
Pancreatitis
More
Clinical
PG-092
 ( CCR2 )		Inflammation
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free